LAURUSLABS1,942.50

Laurus Labs Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABGLANDMANKINDBIOCONALKEMLUPINFORTISGLENMARKMcap ₹1.05L Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
LAURUSLABS
FY26
DIVISLAB
FY26
GLAND
FY26
MANKIND
FY26
Peer
Median
Valuation — at last close
P/E117.94×97.31×47.31×48.46×48.46× +143%
P/B19.31×14.89×4.69×5.60×5.60× +245%
EV/EBITDA60.27×72.47×27.91×26.84×27.91× +116%
Market Cap₹1.05L Cr₹2.49L Cr₹48,604 Cr₹92,715 Cr₹92,715 Cr +13%
Growth
Revenue CAGR 3Y4.09%10.78%21.06%17.73%17.73% -77%
Revenue CAGR 5Y7.19%8.67%13.18%10.93% -34%
Net Income CAGR 3Y3.91%12.09%9.57%13.96%12.09% -68%
Revenue YoY (latest Q)29.10%27.80%19.57%12.89%19.57% +49%
Net Income YoY (latest Q)123.94%65.50%47.09%29.12%47.09% +163%
Profitability
EBITDA Margin26.09%32.59%25.34%25.34%25.34% +3%
Net Income Margin13.07%24.32%15.98%13.57%15.98% -18%
Return on Common Equity16.36%15.32%9.92%11.55%11.55% +42%
Return on Capital Employed18.87%16.55%11.06%12.66%12.66% +49%
Return on Assets8.47%12.82%8.21%6.90%8.21% +3%
Credit & Quality
Total Debt/Equity0.44×0.00×0.02×0.38×0.02× +2100%
Interest Coverage7.60×129.48×36.24×4.27×36.24× -79%
Scale — latest FY
Revenue / Total Income₹6,813 Cr₹10,560 Cr₹6,431 Cr₹14,278 Cr₹10,560 Cr -35%
Net Income₹890 Cr₹2,568 Cr₹1,027 Cr₹1,938 Cr₹1,938 Cr -54%
Total Assets₹10,511 Cr₹20,033 Cr₹12,511 Cr₹28,080 Cr₹20,033 Cr -48%
EPS₹16.47₹96.75₹62.35₹46.35₹62.35 -74%
Book Value per Share₹100.61₹632.49₹628.67₹401.19₹628.67 -84%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.